NCT03676309View on ClinicalTrials.gov

Efficacy and Safety of Nutraceuticals in Patients With Diabetes Mellitus Type II and Dyslipidemia.

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

March 26, 2018

Study Completion Date

March 26, 2018

Conditions
Diabetes Mellitus, Type 2Nutritional and Metabolic DiseasesVascular System InjuryTherapy-Related Morphologic Change
Interventions
DRUG

Nutriceutical Oral Capsule,

nutraceutical 920 mg (Bergamot 450 mg, Gymnema (400 mg, Phaseolamine 30 mg, Olea Europaea 10 mg) twice day , 12 weeks

DRUG

Placebo Oral Tablet

placebo tablet twice a day twenty minutes before main meals, for 12 weeks,

Trial Locations (1)

89819

Capomolla Antonio, Monterosso Calabro

All Listed Sponsors
collaborator

University Magna Graecia

OTHER

lead

Villa dei Gerani

OTHER

NCT03676309 - Efficacy and Safety of Nutraceuticals in Patients With Diabetes Mellitus Type II and Dyslipidemia. | Biotech Hunter | Biotech Hunter